Update on phase I study to evaluate the single- and multiple-dose pharmacokinetics of intravenous hydroxypropyl betacyclodextrin (HPCD) in patients with Niemann-Pick disease type C (NPC-1) and the effects of dosing upon biomarkers of NPC disease